CRISPR Advances
A single infusion of a CRISPR-based therapy has significantly reduced attacks in patients with hereditary angioedema (HAE) in what appears to be the first successful Phase III trial of an in vivo gene-editing treatment. The findings, presented at a major European congress and published in the New England Journal of Medicine, mark a turning point […]
